Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Danavorexton (TAK-925) in Healthy Volunteers and Narcolepsy
NCT03748979Phase 1Completed
- Sponsor
- Takeda
- Start
- Nov 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of danavorexton in narcolepsy (7 arms), sponsored by Takeda. Primary endpoint: Treatment-emergent Adverse Events at Day 15. Started Nov 2018; status: completed.
02
Drugs
danavorexton
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NCT03748979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03748979.